扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及MMP—9、TIMP—1的影响(1)
摘 要：目的 探討扶正化瘀胶囊对稳定期中重度慢性阻塞性肺疾病患者肺功能影响及其可能机制。方法 选取我院136例稳定期中重度慢性阻塞性肺疾病患者，随机分为对照组和实验组，每组68例。对照组予常规治疗，实验组在对照组基础上加用扶正化瘀胶囊，持续8周。比较两组患者治疗前后肺功能(FEV1%、FEV1/FCV)、血清中炎症因子(IL-6、TNF-α)及MMP-9、TIMP-1浓度。结果 治疗后，实验组FEV1%、FEV1/FCV分别为(58.17±6.89)%和(63.57±7.11)，高于对照组的(51.67±5.32)%和(57.87±9.18)，差异具有统计学意义(P<0.05)；实验组IL-6、TNF-α分别为(3.24±1.69)pg/ml和(2.41±0.53)pg/ml，低于对照组的(3.63±1.72)pg/ml和(2.77±0.62)pg/ml，差异具有统计学意义(P<0.05)；实验组MMP-9、TIMP-11分别为(122.16±16.37)ng/ml、(10.32±21.77)ng/ml，低于对照组的(186.32±15.36)ng/ml、(140.13±19.68)ng/ml，差异具有统计学意义(P<0.05)。治疗后实验组MMP-9/TIMP-1比值为(1.11±0.21)，较对照组的(1.31±0.27)更趋于平衡，差异有统计学意义(P<0.05)。结论 扶正化瘀胶囊能改善稳定期慢性阻塞性肺疾病患者肺功能情况，其机制与降低炎症反应及胞外基质沉积相关。
, http://www.100md.com
关键词：慢性阻塞性肺疾病；扶正化瘀胶囊；白细胞介素-6；肿瘤坏死因子-α；基质金属蛋白酶-9；基质金属蛋白酶抑制剂-1
中图分类号：R259 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.14.047
文章编号：1006-1959(2018)14-0152-04
Abstract：Objective To investigate the effect of Fuzheng Huayu Capsule on pulmonary function in patients with moderate to severe chronic obstructive pulmonary disease at stable stage and its possible mechanism.Methods A total of 136 patients with stable moderate to severe chronic obstructive pulmonary disease were randomly divided into control group and experimental group，with 68 cases in each group.The control group received routine treatment，and the experimental group was given Fuzheng Huayu Capsule on the basis of the control group for 8 weeks.The lung function (FEV1%，FEV1/FCV)，serum inflammatory factors (IL-6，TNF-α)，MMP-9 and TIMP-1 concentrations were compared before and after treatment.Results After treatment，the FEV1% and FEV1/FCV of the experimental group were(58.17±6.89)% and(63.57±7.11)，respectively，which were higher than those of the control group(51.67±5.32)% and(57.87±9.18)，the difference was statistically significant(P<0.05)；IL-6 and TNF-α in the experimental group were(3.24±1.69)pg/ml and(2.41±0.53)pg/ml，respectively，which was lower than that of the control group(3.63±1.72)pg/ml and(2.77±0.62)pg/ml，the difference was statistically significant(P<0.05)；The MMP-9 and TIMP-11 in the experimental group were(122.16±16.37)ng/ml and(10.32±21.77) ng/ml，respectively，which was lower than that of the control group(186.32±15.36)ng/ml，(140.13±19.68)ng/ml，the difference was statistically significant(P<0.05).After treatment，the MMP-9/TIMP-1 ratio in the experimental group was(1.11±0.21)，which was more balanced than the control group(1.31±0.27)，and the difference was statistically significant(P<0.05).Conclusion Fuzheng Huayu Capsule can improve the lung function of patients with stable chronic obstructive pulmonary disease，and its mechanism is related to the reduction of inflammatory reaction and extracellular matrix deposition., http://www.100md.com(张林 白俐)
, http://www.100md.com
关键词：慢性阻塞性肺疾病；扶正化瘀胶囊；白细胞介素-6；肿瘤坏死因子-α；基质金属蛋白酶-9；基质金属蛋白酶抑制剂-1
中图分类号：R259 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.14.047
文章编号：1006-1959(2018)14-0152-04
Abstract：Objective To investigate the effect of Fuzheng Huayu Capsule on pulmonary function in patients with moderate to severe chronic obstructive pulmonary disease at stable stage and its possible mechanism.Methods A total of 136 patients with stable moderate to severe chronic obstructive pulmonary disease were randomly divided into control group and experimental group，with 68 cases in each group.The control group received routine treatment，and the experimental group was given Fuzheng Huayu Capsule on the basis of the control group for 8 weeks.The lung function (FEV1%，FEV1/FCV)，serum inflammatory factors (IL-6，TNF-α)，MMP-9 and TIMP-1 concentrations were compared before and after treatment.Results After treatment，the FEV1% and FEV1/FCV of the experimental group were(58.17±6.89)% and(63.57±7.11)，respectively，which were higher than those of the control group(51.67±5.32)% and(57.87±9.18)，the difference was statistically significant(P<0.05)；IL-6 and TNF-α in the experimental group were(3.24±1.69)pg/ml and(2.41±0.53)pg/ml，respectively，which was lower than that of the control group(3.63±1.72)pg/ml and(2.77±0.62)pg/ml，the difference was statistically significant(P<0.05)；The MMP-9 and TIMP-11 in the experimental group were(122.16±16.37)ng/ml and(10.32±21.77) ng/ml，respectively，which was lower than that of the control group(186.32±15.36)ng/ml，(140.13±19.68)ng/ml，the difference was statistically significant(P<0.05).After treatment，the MMP-9/TIMP-1 ratio in the experimental group was(1.11±0.21)，which was more balanced than the control group(1.31±0.27)，and the difference was statistically significant(P<0.05).Conclusion Fuzheng Huayu Capsule can improve the lung function of patients with stable chronic obstructive pulmonary disease，and its mechanism is related to the reduction of inflammatory reaction and extracellular matrix deposition., http://www.100md.com(张林 白俐)